EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

XAB06, a glyco-humanized broad-spectrum anti- Pseudomonas aeruginosa polyclonal antibody, protects mice in a lethal sepsis model

Pierre-Joseph Royer iD, George Graur, Mehdi Varin, Bernard Vanhove iD, Odile Duvaux, Firas Bassissi iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00277-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Pierre-Joseph Royer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Xenothera, Nantes, France. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Sepsis, Antibodies, Bacterial, Pseudomonas Infections. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global rise of antibiotic-resistant Pseudomonas aeruginosa (PA) necessitates the development of novel therapeutic approaches. Polyclonal antibodies constitute a promising approach, as they target multiple bacterial epitopes and functions. Moreover, they have recently demonstrated renewed clinical applicability in their humanized format. We developed a glyco-humanized polyclonal antibody (GH-pAb) targeting PA by immunization of pigs with five PA serotypes frequently encountered in clinical settings. This pentavalent GH-pAb, named XAB06, exhibited binding activity against the five serotypes used for the immunization, as well as unrelated PA serotypes. No binding activity was observed against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, or Acinetobacter baumannii , demonstrating the specificity of XAB06 against PA. In addition, XAB06 showed no reactivity against human blood cells. Functional assays revealed that XAB06 significantly inhibited swarming motility, biofilm formation, and pyocyanin production, indicating interference with key virulence determinants of PA. Notably, XAB06 conferred protection in a murine model of sepsis using the reference strains PAO1, PA103, and a ST235 high-risk clone. Collectively, these findings demonstrate the broad PA coverage and the protective activity of XAB06, supporting its potential as a novel therapeutic strategy against PA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaSepsisAntibodies, BacterialPseudomonas InfectionsAnti-Bacterial AgentsAnimalsMiceHumansDisease Models, AnimalBiofilmsSwineFemaleEnterobacter cloacaeMice, Inbred BALB C

Stichwörter der Autor:innen

Pseudomonas aeruginosaglyco-humanized polyclonal antibody

Substanzen

Antibodies, BacterialAnti-Bacterial Agents

Autor:innen und Institutionen

  • Xenothera, Nantes, France.

ORCID-Profile: Pierre-Joseph Royer, Bernard Vanhove, Firas Bassissi

Zitieren

APA

Royer, P. J., Graur, G., Varin, M., Vanhove, B., Duvaux, O., & Bassissi, F. (2026). XAB06, a glyco-humanized broad-spectrum anti- Pseudomonas aeruginosa polyclonal antibody, protects mice in a lethal sepsis model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00277-26

Vancouver

Royer PJ, Graur G, Varin M, Vanhove B, Duvaux O, Bassissi F. XAB06, a glyco-humanized broad-spectrum anti- Pseudomonas aeruginosa polyclonal antibody, protects mice in a lethal sepsis model. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00277-26

BibTeX
@article{Royer2026,
  author = {Royer, Pierre-Joseph and Graur, George and Varin, Mehdi and Vanhove, Bernard and Duvaux, Odile and Bassissi, Firas},
  title = {XAB06, a glyco-humanized broad-spectrum anti- Pseudomonas aeruginosa polyclonal antibody, protects mice in a lethal sepsis model},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00277-26}
}
Kostenlos starten →